Lurasidone
ApprovedTerminated 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia
Trial Timeline
Dec 30, 2021 → Nov 18, 2022
NCT ID
NCT05213143About Lurasidone
Lurasidone is a approved stage product being developed by Sumitomo Pharma for Schizophrenia. The current trial status is terminated. This product is registered under clinical trial identifier NCT05213143. Target conditions include Schizophrenia.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05213143 | Approved | Terminated |
| NCT05011669 | Approved | Completed |
| NCT01575561 | Phase 3 | Completed |
| NCT01620060 | Phase 1 | Completed |
| NCT01566162 | Phase 3 | Completed |
| NCT01423253 | Phase 3 | Completed |
| NCT01485640 | Phase 3 | Completed |
| NCT00868959 | Phase 3 | Completed |
| NCT01082289 | Phase 1 | Completed |
| NCT01082146 | Phase 1 | Completed |
Competing Products
20 competing products in Schizophrenia